Jupiter Neurosciences, Inc. (JUNS)
JUNS Stock Price Chart
Explore Jupiter Neurosciences, Inc. interactive price chart. Choose custom timeframes to analyze JUNS price movements and trends.
JUNS Company Profile
Discover essential business fundamentals and corporate details for Jupiter Neurosciences, Inc. (JUNS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jan 2022
Employees
4.00
Website
https://www.jupiterorphan.comCEO
Christer Rosen
Description
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
JUNS Financial Timeline
Browse a chronological timeline of Jupiter Neurosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.05, while revenue estimate is $400.00k.
Earnings released on 14 May 2026
EPS came in at -$0.06 falling short of the estimated -$0.05 by -20.00%, while revenue for the quarter reached $18.65k , missing expectations by -91.71%.
Earnings released on 1 Apr 2026
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $21.80k , missing expectations by -70.94%.
Earnings released on 14 Nov 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%.
Earnings released on 18 Aug 2025
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 15 May 2025
EPS came in at -$0.05 falling short of the estimated -$0.03 by -66.67%.
Earnings released on 28 Mar 2025
EPS came in at -$0.05 falling short of the estimated -$0.02 by -150.00%.
Earnings released on 23 Dec 2024
EPS came in at -$0.02 .
Earnings released on 30 Jun 2024
EPS came in at $0.01 .
Earnings released on 31 Mar 2024
EPS came in at -$0.02 .
Earnings released on 31 Dec 2023
EPS came in at -$0.01 .
Earnings released on 30 Sept 2023
EPS came in at -$0.07 .
Earnings released on 30 Jun 2023
EPS came in at -$0.03 .
Earnings released on 31 Mar 2023
EPS came in at -$0.04 .
Earnings released on 30 Jun 2022
EPS came in at -$0.08 , while revenue for the quarter reached $233.28k .
Earnings released on 31 Mar 2022
EPS came in at -$0.07 .
Earnings released on 31 Dec 2021
EPS came in at -$0.23 .
Earnings released on 30 Sept 2021
EPS came in at -$0.14 .
JUNS Stock Performance
Access detailed JUNS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
